重组人脑利钠肽治疗心肾综合征疗效研究

目的：观察重组人脑利钠肽（rhBNP）治疗心肾综合征患者的疗效。方法：回顾性分析在我院住院诊断为心肾综合征的患者75例的资料，按数字表法被随机分为：常规治疗组（40例，给予常规治疗），rhBNP组（35例，在常规治疗的基础上加用 rhBNP），rhBNP按0.0075μg·kg^-1·min^-1以微量泵静脉泵入，每天1次，每次持续约10 h，7d为1疗程，分别记录治疗前和7d后患者的24 h尿量、N末端脑利钠肽前体（NT-proBNP）、肾小球滤过率及心脏彩超的变化。结果：治疗后与常规治疗组比较， rhBNP 组总有效率（62.5％比94.3％），24 h 尿量[（785.2±143.4）ml比（965.34±171.8）ml]、肾小球滤过率[（34.1±2.6）ml/min比（45.2±5.6）ml/min]、左室射血分数[（35.6±5.5）％比（45.9±6.8）％]显著升高，NT-proBNP [（3451.1±1314.2）pg/ml 比（1516.43±431.52）pg/ml]水平显著降低，差异有统计学意义（P均＜0.01）。结论：重组人脑利钠肽在心肾综合征患者治疗中安全有效，并能改善肾功能。

Therapeutic effect of recombinant human brain natriuretic peptide on cardiorenal syndrome

Objective：To observe the therapeutic effect of recombinant human brain natriuretic peptide （rhBNP）on patients with cardiorenal syndrome.Methods：The data of 75 patients,who were diagnosed as cardiorenal syndrome and hospitalized in our hospital,were retrospectively analyzed.They were randomly divided into routine treatment group （n=40,received routine treatment）and rhBNP group （n=35,received rhBNP based on routine treatment） according to number table method.The rhBNP was pumped with 0.0075μg·kg^-1 ·min^-1 using micropump intravenously,once/day,about 10h/time and 7d was regarded as a course of treatment.Changes of 24h urine volume,N terminal pro brain natriuretic peptide （NT-proBNP）,glomerular filtration rate （GFR）and echocardiograph were recorded in all patients before and 7d after treatment.Results：Compared with routine treatment group after treatment,there were significant increase in total effective rate （62.5% vs.94.3%）,24h urine volume [（785.2 ± 143.4）ml vs.（965.34±171.8）ml],GFR [（34.1±2.6）ml/min vs.（45.2±5.6）ml/min]and left ventricular ejection fraction [（35.6±5.5）% vs.（45.9±6.8）%],and significant reduction in NT-proBNP level [（3451.1± 1314.2）pg/ml vs.（1516.43 ± 431.52）pg/ml]in rhBNP group,P〈0.01 all.Conclusion：Recombinant human brain natriuretic peptide is safe,effective and can improve renal function in treating patients with cardiorenal syn-drome.